The Effect of Immunized Platelet Transfusion Refractoriness on Allo-HSCT Patients with Malignant Hematological Diseases / 中国实验血液学杂志

OBJECTIVE@#To investigate the characteristics of platelet antibody in patients with hematological diseases, so as to research the effect of immunized platelet transfusion refractoriness (PTR) on the prognosis of allogeneic hematopoietic stem cell transplantation (allo-HSCT) recepients with malignant hematological diseases patients.@*METHODS@#The clinical data of platelet antibody positive patients tested by Capture-P in the First Affiliated Hospital of Soochow University from July 1, 2014 to July 1, 2019 were retrospectively analyzed, including sex, age, disease, platelet transfusion assessments, CD34@*RESULTS@#In 5 years, 913 (7.28%) hematologic patients with platelet antibody positive were identified, the detection rate of females (513 cases) were higher than males (400 cases). Among the 913 patients, the antibody positive rates of 520 patients with malignant hematological diseases (acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome) showed significantly statistical different (10.27%, 8.01%, and 7.20%) (P<0.01), and the positive rate of the acute myeloid leukemia of those patients was higher than myelodysplastic syndrome patients(α<0.0125). There were 35 cases diagnosed as immunized PTR before allo-HSCT, the platelet increments, 14 h correct count increment, progression-free survival rate and overall survival rate of those patients were significantly lower than those in negative transfusion effective patients (P<0.01), while the percentage of ABO matching was significantly higher (α<0.0125).@*CONCLUSION@#The positive rate of platelet antibody identification is high in females and acute myeloid leukemia patients, and immunized PTR caused by antibody is a risk factor for poor prognosis of allo-HSCT in malignant hematological disease patients.

Progress of study on interaction between platelets and endothelial cells / 中国实验血液学杂志

Endothelial lesion is the most well known example for the interaction between platelets and endothelial cells, but the recent researches indicate that platelets and endothelial cells also participate in inflammation, tumor metastasis and lymphovascular development. Under these situations, the activated platelets express adhesive molecules and degranulate, and regulate the permeability, adhesion, survival, proliferation and metastasis of endothelial cells. All the achievements push the research on the interaction between platelets and endothelial cells to a new era, which would be more significant. In this review, the latest advances and prospect of the interaction between platelets and endothelial cells in inflammation, tumor and lymphovascular development are summarized.